Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 4Terminated 2Recruiting 2Active not recruiting 2No longer available 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 3Myeloid 2Other neoplasm 1Classical hematology 1

Conditions

Myelodysplastic Syndromes 187Leukemia, Myeloid, Acute 159Myeloproliferative Disorders 83Leukemia, Myelogenous, Chronic, BCR-ABL Positive 72Precursor Cell Lymphoblastic Leukemia-Lymphoma 61Primary Myelofibrosis 54Leukemia, Myelomonocytic, Chronic 44Leukemia 35Polycythemia Vera 33Multiple Myeloma 30Hematologic Neoplasms 30Thrombocythemia, Essential 29Lymphoma, Non-Hodgkin 28Leukemia, Biphenotypic, Acute 25Hodgkin Disease 25Lymphoma 23Myelodysplastic-Myeloproliferative Diseases 18Leukemia, Lymphocytic, Chronic, B-Cell 18Leukemia, Myeloid, Chronic-Phase 14Blastic Plasmacytoid Dendritic Cell Neoplasm 14Neoplasms 13Burkitt Lymphoma 12Mastocytosis 11Leukemia, Myeloid 11Graft vs Host Disease 11Blast Crisis 11Anemia, Refractory, with Excess of Blasts 11Lymphoma, Follicular 10Anemia, Aplastic 10Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8

Interventions

venetoclax 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Preleukemia × Myeloid × Clear all
NCT07216443 2026-04-15

Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Orca Biosystems, Inc.

Phase 2 Recruiting
80 enrolled
MyeloidOther hematologic neoplasmOther neoplasm

Acute Disease, Bone Marrow Diseases, Disease, Graft vs Host Disease, Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Myelodysplastic Syndromes, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Pathologic Processes, Precancerous Conditions, Preleukemia, Syndrome, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Disease Attributes

NCT06501196 2025-09-24

A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome

BlossomHill Therapeutics

Phase 1 Recruiting
170 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Leukemia, Myeloid, Myelodysplastic Syndromes, Preleukemia, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡